Neuroscientific Biopharmaceuticals Ltd. (NSB) AI Stock Analysis

• Market Cap: AU$7.52M
• Dividend Yield: N/A
• Average Volume (3M): 518.82K
• Price to Earnings (P/E): 6.3
• Beta (1Y): -0.05
• Revenue Growth: N/A
• EPS Growth: 51.85%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 54
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 144,604,870
• 10 Day Avg. Volume: 219,940
• 30 Day Avg. Volume: 518,817
• PEG Ratio: 0.12
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Neuroscientific Biopharmaceuticals Ltd. is facing substantial financial challenges, including volatile revenue and ongoing operational inefficiencies. However, the stock shows positive technical momentum and appears undervalued, providing a mixed outlook. Investors should weigh the financial performance concerns against the potential for an undervalued investment with upside momentum.

Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Neuroscientific Biopharmaceuticals Ltd. (NSB) is a biotechnology company specializing in the development of novel peptide-based pharmaceutical products targeting neurodegenerative conditions. The company operates within the pharmaceutical and biotechnology sectors, focusing on creating innovative therapies for diseases such as Alzheimer's, Parkinson's, and Multiple Sclerosis. NSB's core product portfolio includes patented compounds aimed at enhancing neuron survival and regeneration.

How the Company Makes Money

Neuroscientific Biopharmaceuticals Ltd. generates revenue primarily through the development and commercialization of its proprietary pharmaceutical products. The company's key revenue streams include licensing agreements with larger pharmaceutical companies, milestone payments, and royalties from product sales. NSB may also engage in research collaborations and partnerships with academic institutions and research organizations to advance its drug development programs. Additionally, the company might receive grants and funding from government and non-government organizations to support its research initiatives.

Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	4.95M	0.00	958.77K	0.00
	Gross Profit
-91.34K	4.90M	-64.92K	897.36K	-56.66K
	EBIT
-2.06M	-6.12M	-10.50M	-4.22M	-2.94M
	EBITDA
-1.80M	-5.96M	-10.37M	-3.12M	-2.81M
	Net Income Common Stockholders
324.21K	-1.07M	-10.44M	-3.18M	-2.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.95M	4.91M	7.22M	14.16M	3.29M
	Total Assets
5.44M	5.29M	7.74M	14.83M	3.74M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-4.95M	-4.91M	-7.22M	-14.16M	-3.29M
	Total Liabilities
85.68K	597.36K	2.22M	223.41K	88.53K
	Stockholders Equity
5.35M	4.69M	5.52M	14.60M	3.65M
Cash Flow		Free Cash Flow
42.43K	-2.30M	-6.95M	-2.63M	-2.28M
	Operating Cash Flow
44.25K	-2.30M	-6.94M	-2.60M	-2.28M
	Investing Cash Flow
-1.81K	0.00	-3.87K	-29.88K	-2.38K
	Financing Cash Flow
0.00	0.00	0.00	13.51M	960.80K

Neuroscientific Biopharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Positive. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 59.38 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NSB.

Neuroscientific Biopharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NSB	54 Neutral	AU$7.52M	6.34	26.99%	―	―	51.85%
RAC	54 Neutral	AU$202.39M	―	-37.20%	―	―	32.02%
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%
ACW	45 Neutral	$85.78M	―	-55.44%	―	―	49.25%
IMU	37 Underperform	AU$164.27M	―	-99.05%	―	―	-34.09%
BIT	36 Underperform	$3.98M	―	-119.28%	―	―	64.10%

Neuroscientific Biopharmaceuticals Ltd. Corporate Events

NeuroScientific Biopharmaceuticals Expands with New Acquisitions and Research Initiatives

NeuroScientific Biopharmaceuticals Ltd has announced preparations for two IND-enabling pre-clinical studies for EmtinB, targeting advanced glaucoma. Additionally, the company is acquiring StemSmart technology from Isopogen WA, which involves the use of mesenchymal stromal cells (MSC) derived from adult human donor bone marrow to treat various serious conditions. This acquisition positions NeuroScientific to expand its offerings in the cellular medicine market, with potential impacts on markets such as Crohn’s disease and organ transplant immuno-suppressants. The company has also secured $3.5 million in funding to support these initiatives.

Neuroscientific Biopharmaceuticals Announces Proposed Securities Issue

Neuroscientific Biopharmaceuticals Ltd announced a proposed issue of securities, including 40 million options exercisable at $0.07 and 100 million fully paid ordinary shares. This move is expected to enhance the company’s financial resources and potentially strengthen its market position, allowing it to further its research and development efforts in the biopharmaceutical field.

NeuroScientific Biopharmaceuticals Expands into Stem Cell Therapy with StemSmart Acquisition

NeuroScientific Biopharmaceuticals Ltd announced its acquisition of StemSmart, a patented stem cell technology from Isopogen WA, which is expected to enhance its portfolio and position in regenerative medicine. This acquisition includes a Special Access Program for treating fistulising Crohn’s disease, with promising early results from a Phase 2 trial. The company is also raising $3.5 million to support this expansion and has proposed new appointments to its board, signaling a strategic move to leverage the growing global recognition of stem cell therapies.

NeuroScientific Biopharmaceuticals Initiates Trading Halt for Major Announcement

NeuroScientific Biopharmaceuticals Ltd. announced a trading halt on its securities pending an announcement related to an acquisition and capital raising. This move is significant for the company as the acquisition and capital raising are considered material to its operations, potentially impacting its market positioning and stakeholder interests.

NeuroScientific Biopharmaceuticals Reports Revenue Growth and Reduced Losses

NeuroScientific Biopharmaceuticals Limited reported a 5% increase in revenues for the half-year ending December 2024, while significantly reducing its loss by 70% compared to the previous period. Despite not declaring a dividend, the company improved its net tangible assets per share from 2.44 cents to 3.23 cents, indicating a stronger financial position.